Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability
- 29 March 2013
- journal article
- review article
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 15 (5) , 1-11
Abstract
This systematic review examines treatment guidelines, efficacy/effectiveness, and tolerability regarding the use of antipsychotics concurrently with psychostimulants in treating aggression and hyperactivity in children and adolescents. Articles examining the concurrent use of antipsychotics and psychostimulants to treat comorbid attention deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs) were identified and their results were summarized and critically analyzed. Antipsychotic and stimulant combination therapy is recommended by some guidelines, but only as a third-line treatment following stimulant monotherapy and stimulants combined with behavioral interventions to treat aggression in patients with ADHD. Some studies suggest efficacy/effectiveness for an antipsychotic and stimulant combination in the treatment of aggression and hyperactivity in children and adolescents. However, the data do not clearly demonstrate superiority compared to antipsychotic or psychostimulant monotherapy. Most studies were performed over short time periods, several lacked blinding, few studies used any placebo control, and no comparisons were made with behavioral interventions. There are concerns about the tolerability of combination therapy, but data do not suggest significantly worse adverse effects for combination compared to either antipsychotic or stimulant monotherapy. Conversely, and contrary to speculation, use of a stimulant does not significantly reduce metabolic effects of antipsychotics. Combination treatment with antipsychotics and psychostimulants is used frequently, and increasingly more often. Few studies have directly examined this combination for the treatment of ADHD and DBDs. Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents.Keywords
This publication has 48 references indexed in Scilit:
- Atypical antipsychotics for disruptive behaviour disorders in children and youths2012
- Developments in Pediatric PsychopharmacologyThe Journal of Clinical Psychiatry, 2011
- A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor SymptomsJournal of Clinical Psychopharmacology, 2010
- National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment SettingThe Journal of Clinical Psychiatry, 2010
- Methylphenidate Combined with Aripiprazole in Children and Adolescents with Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover TrialJournal of Child and Adolescent Psychopharmacology, 2009
- Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or OppositionalityJournal of Child and Adolescent Psychopharmacology, 2009
- Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysisEuropean Child & Adolescent Psychiatry, 2009
- Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and AdolescentsJournal of Child and Adolescent Psychopharmacology, 2009
- Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy ChallengesHealth Affairs, 2009